Histone	B-GP
hypo	O
-	O
acetylation	O
of	O
Sox9	B-GP
mediates	O
nicotine	O
-	O
induced	O
weak	O
cartilage	O
repair	O
by	O
suppressing	O
BMSC	O
chondrogenic	O
differentiation	O

Background	O

Nicotine	O
has	O
negative	O
effects	O
on	O
tissue	O
repair	O
,	O
little	O
research	O
concerns	O
its	O
effect	O
on	O
the	O
cartilage	O
repair	O
of	O
tissue	O
engineering	O
stem	O
cells	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
nicotine	O
on	O
the	O
bone	O
marrow	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
’	O
(	O
BMSCs	O
)	O
chondrogenic	O
repair	O
function	O
of	O
cartilage	O
defects	O
and	O
explored	O
the	O
molecular	O
mechanism	O
.	O

Methods	O

A	O
cartilage	O
defect	O
model	O
of	O
rat	B-OG
was	O
repaired	O
by	O
BMSC	O
transplantation	O
,	O
and	O
treated	O
with	O
nicotine	O
or	O
saline	O
at	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
in	O
12	O
weeks	O
.	O

Nicotine	O
’	O
s	O
effect	O
on	O
chondrogenic	O
differentiation	O
was	O
studied	O
by	O
exposing	O
BMSCs	O
to	O
nicotine	O
at	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100	O
μM	O
,	O
and	O
methyllycaconitine	O
(	O
MLA	O
),	O
which	O
is	O
a	O
selective	O
α7	B-GP
-	I-GP
nicotinic	I-GP
acetylcholine	I-GP
receptor	I-GP
(	O
nAChR	B-GP
)	O
inhibitor	O
and	O
si	O
-	O
RNA	O
of	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	I-GP
2	I-GP
(	O
NFATc2	B-GP
),	O
were	O
used	O
to	O
verify	O
the	O
molecular	O
mechanism	O
of	O
nicotine	O
’	O
s	O
effect	O
.	O

Results	O

Data	O
showed	O
that	O
nicotine	O
inhibited	O
cartilage	O
repair	O
function	O
by	O
suppressing	O
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP
(	O
Sox9	B-GP
)	O
in	O
regenerated	O
tissues	O
.	O

Further	O
in	O
vitro	O
study	O
demonstrated	O
that	O
nicotine	O
enhanced	O
intracellular	O
Ca2	O
+	O
and	O
activity	O
of	O
calcineurin	B-GP
(	O
CaN	B-GP
)	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
increased	O
the	O
nucleic	O
expressions	O
of	O
NFATc2	B-GP
and	O
the	O
bindings	O
to	O
SOX9	B-GP
promoter	O
,	O
and	O
thus	O
reduced	O
the	O
acetylation	O
of	O
H3K9	O
and	O
H3K14	O
in	O
SOX9	B-GP
promoter	O
.	O

Conclusions	O

Findings	O
from	O
this	O
study	O
demonstrated	O
that	O
nicotine	O
suppressed	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
which	O
offers	O
insight	O
into	O
the	O
risk	O
assessment	O
of	O
cartilage	O
defect	O
repair	O
in	O
a	O
nicotine	O
exposure	O
population	O
and	O
its	O
therapeutic	O
target	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13287	O
-	O
018	O
-	O
0853	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

Articular	O
cartilage	O
is	O
composed	O
of	O
chondrocytes	O
and	O
extracellular	O
matrix	O
,	O
which	O
primarily	O
consists	O
of	O
collagen	B-GP
II	I-GP
and	O
proteoglycans	B-GP
[	O
1	O
].	O

It	O
covers	O
the	O
metaphysis	O
of	O
long	O
bones	O
and	O
provides	O
shock	O
absorption	O
and	O
lubrication	O
to	O
diarthrodial	O
joints	O
.	O

Cartilage	O
tissue	O
has	O
poor	O
self	O
-	O
healing	O
capacity	O
because	O
it	O
is	O
avascular	O
and	O
thus	O
has	O
inadequate	O
access	O
to	O
progenitor	O
cells	O
from	O
blood	O
and	O
bone	O
marrow	O
(	O
BM	O
),	O
which	O
facilitate	O
regeneration	O
[	O
2	O
].	O

The	O
articular	O
cartilage	O
defect	O
is	O
accompanied	O
by	O
pain	O
and	O
loss	O
of	O
function	O
,	O
and	O
progressive	O
breakdown	O
leads	O
to	O
degenerative	B-DS
disorders	I-DS
,	O
such	O
as	O
osteoarthritis	B-DS
,	O
which	O
can	O
seriously	O
affect	O
a	O
patient	O
’	O
s	O
life	O
and	O
work	O
.	O

Epidemiological	O
studies	O
had	O
indicated	O
that	O
cartilage	O
defects	O
were	O
found	O
in	O
60	O
%	O
of	O
patients	O
who	O
undergone	O
arthroscopic	O
surgery	O
and	O
that	O
the	O
main	O
population	O
included	O
young	O
adults	O
[	O
3	O
].	O

Therefore	O
,	O
the	O
optional	O
repair	O
and	O
regeneration	O
of	O
cartilage	O
defect	O
is	O
an	O
important	O
issue	O
in	O
medical	O
research	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
can	O
be	O
isolated	O
from	O
various	O
tissues	O
and	O
can	O
differentiate	O
into	O
chondrogenic	O
lineage	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
,	O
5	O
].	O

In	O
2002	O
,	O
Wakitani	O
et	O
al	O
.	O
[	O
6	O
]	O
applied	O
bone	O
marrow	O
mesenchymal	O
stem	O
cell	O
(	O
BMSC	O
)	O
transplantations	O
to	O
repair	O
human	B-OG
articular	O
cartilage	O
defects	O
in	O
osteoarthritic	O
knee	O
joints	O
and	O
observed	O
that	O
the	O
cartilage	O
defects	O
were	O
partially	O
covered	O
with	O
hyaline	O
cartilage	O
-	O
like	O
tissue	O
,	O
which	O
highlighted	O
the	O
availability	O
of	O
autologous	O
culture	O
-	O
expanded	O
BMSC	O
transplantation	O
for	O
the	O
repair	O
of	O
articular	O
cartilage	O
defects	O
in	O
humans	B-OG
.	O

Since	O
then	O
,	O
numerous	O
studies	O
on	O
using	O
BMSCs	O
to	O
repair	O
cartilage	O
lesions	O
,	O
from	O
preclinical	O
findings	O
to	O
clinical	O
application	O
,	O
have	O
been	O
performed	O
as	O
BMSCs	O
can	O
be	O
easily	O
obtained	O
and	O
used	O
[	O
7	O
].	O

The	O
transplantation	O
of	O
BMSCs	O
has	O
become	O
one	O
of	O
the	O
main	O
methods	O
for	O
treating	O
cartilage	O
defects	O
[	O
8	O
–	O
10	O
].	O

However	O
,	O
the	O
majority	O
focused	O
on	O
how	O
to	O
optimize	O
the	O
microenvironment	O
or	O
improve	O
the	O
efficiency	O
of	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
and	O
there	O
was	O
no	O
concern	O
about	O
adverse	O
factors	O
in	O
the	O
differentiation	O
process	O
.	O

As	O
a	O
key	O
component	O
of	O
smoking	O
,	O
nicotine	O
has	O
negative	O
effects	O
on	O
tissue	O
repair	O
and	O
healing	O
[	O
11	O
,	O
12	O
].	O

An	O
epidemiological	O
study	O
had	O
demonstrated	O
that	O
nicotine	O
abuse	O
was	O
a	O
high	O
-	O
risk	O
factor	O
that	O
influences	O
the	O
clinical	O
outcome	O
of	O
cartilage	O
defects	O
repair	O
of	O
the	O
knee	O
[	O
13	O
].	O

Our	O
previous	O
study	O
indicated	O
that	O
prenatal	O
nicotine	O
exposure	O
induced	O
fetal	O
articular	O
dyschondroplasia	B-DS
[	O
14	O
].	O
The	O
epiphyseal	O
cartilage	O
development	O
is	O
a	O
process	O
of	O
proliferation	O
and	O
differentiation	O
of	O
MSCs	O
[	O
15	O
],	O
in	O
which	O
nicotine	O
can	O
interfere	O
with	O
the	O
chondrogenic	O
differentiation	O
of	O
MSCs	O
in	O
vivo	O
.	O

The	O
process	O
of	O
repairing	O
cartilage	O
defects	O
is	O
also	O
a	O
process	O
of	O
chondrogenic	O
differentiation	O
of	O
stem	O
cells	O
[	O
16	O
];	O
therefore	O
,	O
nicotine	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
the	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defects	O
.	O

Our	O
previous	O
work	O
has	O
demonstrated	O
that	O
nicotine	O
could	O
suppress	O
the	O
chondrogenic	O
differentiation	O
potential	O
of	O
BMSCs	O
and	O
result	O
in	O
poorly	O
differentiated	O
cartilage	O
[	O
17	O
].	O

However	O
,	O
the	O
mechanism	O
is	O
still	O
unclear	O
.	O

SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP
(	O
Sox9	B-GP
)	O
is	O
a	O
key	O
regulator	O
and	O
controls	O
the	O
expression	O
of	O
the	O
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
(	O
Col2A1	B-GP
)	O
gene	O
in	O
the	O
initiation	O
stage	O
of	O
MSC	O
chondrogenic	O
differentiation	O
[	O
18	O
].	O

During	O
primary	O
chondrogenesis	O
,	O
which	O
is	O
activated	O
by	O
transforming	B-GP
growth	I-GP
factor	I-GP
beta	I-GP
(	O
TGF	B-GP
-	I-GP
β	I-GP
),	O
Sox9	B-GP
binds	O
to	O
essential	O
sequences	O
in	O
the	O
Col2A1	B-GP
gene	O
enhancers	O
and	O
initiates	O
its	O
expression	O
[	O
19	O
].	O
The	O
functional	O
modulation	O
of	O
Sox9	B-GP
is	O
a	O
critical	O
step	O
for	O
the	O
initiation	O
of	O
chondrogenesis	O
and	O
is	O
mainly	O
regulated	O
by	O
histone	B-GP
acetylation	O
[	O
20	O
].	O

The	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	I-GP
(	O
NFAT	B-GP
)	O
transcription	B-GP
factor	I-GP
NFATp	B-GP
(	O
NFATc2	B-GP
)	O
is	O
a	O
repressor	O
of	O
chondrogenesis	O
[	O
21	O
]	O
and	O
can	O
interact	O
with	O
histone	B-GP
deacetylase	I-GP
(	O
HDAC	B-GP
)	O
proteins	O
to	O
induce	O
gene	O
silencing	O
[	O
22	O
].	O

Calcineurin	B-GP
(	O
CaN	B-GP
),	O
an	O
upstream	O
molecule	O
of	O
NFATc2	B-GP
,	O
is	O
induced	O
by	O
increased	O
Ca2	O
+	O
and	O
can	O
translocate	O
the	O
dephosphorylated	O
NFATc2	B-GP
into	O
the	O
nucleus	O
[	O
23	O
].	O

The	O
stimulus	O
of	O
nicotine	O
can	O
increase	O
the	O
intracellular	O
Ca2	O
+	O
of	O
MSCs	O
through	O
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP
(	O
nAChR	B-GP
)	O
[	O
24	O
].	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
nicotine	O
could	O
decrease	O
Sox9	B-GP
’	O
s	O
promoter	O
histone	B-GP
acetylation	O
and	O
inhibit	O
its	O
expression	O
through	O
HDAC	B-GP
recruitment	O
by	O
the	O
activated	O
nAChR	B-GP
/	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFAT	B-GP
pathway	O
in	O
BMSCs	O
.	O

In	O
this	O
study	O
,	O
we	O
confirmed	O
that	O
nicotine	O
interfered	O
with	O
BMSC	O
transplantation	O
repair	O
of	O
cartilage	O
defects	O
by	O
inhibiting	O
Sox9	B-GP
expression	O
in	O
vivo	O
and	O
that	O
nicotine	O
-	O
induced	O
Sox9	B-GP
gene	O
suppression	O
via	O
nAChRs	B-GP
is	O
mediated	O
directly	O
by	O
decreasing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
.	O

Methods	O

Animal	B-OG
studies	O

Animal	B-OG
experiments	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Committee	O
on	O
the	O
Ethics	O
of	O
Animal	B-OG
Experiments	O
of	O
the	O
Wuhan	O
University	O
School	O
of	O
Medicine	O
(	O
No	O
.	O
14016	O
).	O

The	O
animal	B-OG
experimental	O
procedures	O
were	O
performed	O
in	O
accordance	O
with	O
the	O
Guidelines	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	B-OG
(	O
eighth	O
edition	O
)	O
from	O
the	O
National	O
Research	O
Council	O
of	O
the	O
United	O
States	O
National	O
Academies	O
,	O
and	O
performed	O
in	O
the	O
Center	O
for	O
Animal	B-OG
Experiment	O
of	O
Wuhan	O
University	O
(	O
Wuhan	O
,	O
China	O
),	O
which	O
was	O
accredited	O
by	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
of	O
Laboratory	O
Animal	B-OG
Care	O
International	O
(	O
AAALAC	O
International	O
).	O

Female	O
(	O
weighing	O
180	O
–	O
220	O
g	O
)	O
and	O
male	O
(	O
weighing	O
260	O
–	O
300	O
g	O
)	O
Wistar	B-OG
rats	I-OG
at	O
12	O
weeks	O
old	O
were	O
obtained	O
from	O
the	O
Experimental	O
Center	O
of	O
the	O
Medical	O
Scientific	O
Academy	O
of	O
Hubei	O
(	O
no	O
.	O
2008	O
–	O
0005	O
).	O

Rats	B-OG
were	O
housed	O
in	O
metal	O
cages	O
with	O
wire	O
-	O
mesh	O
floors	O
in	O
an	O
air	O
-	O
conditioned	O
room	O
under	O
standard	O
conditions	O
(	O
room	O
temperature	O
:	O
18	O
–	O
22	O
°	O
C	O
;	O
humidity	O
:	O
40	O
–	O
60	O
%;	O
light	O
cycle	O
:	O
12	O
h	O
light	O
-	O
dark	O
cycle	O
;	O
10	O
–	O
15	O
air	O
changes	O
per	O
hour	O
)	O
and	O
allowed	O
free	O
access	O
to	O
rat	B-OG
chow	O
and	O
tap	O
water	O
.	O

Rats	B-OG
were	O
randomly	O
distributed	O
into	O
control	O
(	O
BMSCs	O
)	O
and	O
experimental	O
(	O
BMSCs	O
+	O
nicotine	O
)	O
groups	O
(	O
n	O
=	O
8	O
for	O
each	O
group	O
).	O

The	O
cartilage	O
defect	O
model	O
in	O
the	O
two	O
groups	O
followed	O
the	O
method	O
described	O
by	O
Chung	O
et	O
al	O
.	O
[	O
25	O
].	O

In	O
brief	O
,	O
anesthesia	O
was	O
performed	O
with	O
an	O
intraperitoneal	O
injection	O
of	O
3	O
.	O
5	O
ml	O
/	O
kg	O
of	O
10	O
%	O
chloral	O
hydrate	O
.	O

In	O
each	O
case	O
,	O
after	O
cleaning	O
with	O
10	O
%	O
betadine	O
solution	O
,	O
right	O
knee	O
joints	O
of	O
each	O
rat	B-OG
were	O
sterilely	O
draped	O
and	O
opened	O
using	O
an	O
anteromedial	O
approach	O
.	O

The	O
patellae	O
were	O
laterally	O
dislocated	O
,	O
and	O
full	O
-	O
thickness	O
articular	O
cartilage	O
defects	O
(	O
2	O
mm	O
in	O
diameter	O
)	O
were	O
created	O
in	O
trochlear	O
grooves	O
by	O
carefully	O
drilling	O
in	O
a	O
vertical	O
direction	O
using	O
a	O
2	O
-	O
mm	O
drill	O
.	O

Drilling	O
was	O
performed	O
in	O
3	O
mm	O
deep	O
through	O
subchondral	O
bone	O
.	O

After	O
removing	O
cartilage	O
and	O
bone	O
debris	O
,	O
boundaries	O
around	O
the	O
drill	O
were	O
trimmed	O
using	O
a	O
surgical	O
knife	O
and	O
washed	O
out	O
.	O

The	O
mixture	O
containing	O
BMSCs	O
(	O
2	O
×	O
106	O
cells	O
/	O
ml	O
)	O
and	O
1	O
.	O
25	O
%	O
alginate	O
in	O
0	O
.	O
15	O
M	O
saline	O
[	O
26	O
]	O
was	O
then	O
transplanted	O
into	O
the	O
full	O
-	O
thickness	O
defect	O
in	O
the	O
right	O
knee	O
.	O

Following	O
implantation	O
,	O
patellar	O
retinaculum	O
and	O
overlying	O
soft	O
tissues	O
were	O
closed	O
in	O
layers	O
.	O

Rats	B-OG
were	O
allowed	O
to	O
move	O
knee	O
joints	O
freely	O
in	O
their	O
cages	O
without	O
restriction	O
.	O

An	O
intraperitoneal	O
injection	O
of	O
4	O
×	O
105	O
U	O
of	O
penicillin	O
(	O
Harbin	O
Pharmaceutical	O
Group	O
,	O
Shanghai	O
,	O
China	O
)	O
was	O
administered	O
immediately	O
after	O
implantation	O
and	O
once	O
daily	O
for	O
1	O
week	O
.	O

Clinical	O
signs	O
were	O
observed	O
daily	O
during	O
the	O
study	O
period	O
.	O

Animals	B-OG
were	O
sacrificed	O
at	O
12	O
weeks	O
post	O
-	O
implantation	O
to	O
assess	O
cartilage	O
repair	O
statuses	O
.	O

The	O
experimental	O
group	O
was	O
injected	O
with	O
nicotine	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
at	O
1	O
.	O
0	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
).	O

As	O
a	O
preliminary	O
study	O
,	O
defects	O
of	O
the	O
same	O
size	O
(	O
2	O
mm	O
diameter	O
and	O
3	O
mm	O
deep	O
)	O
were	O
created	O
,	O
and	O
the	O
cartilage	O
repair	O
with	O
no	O
treatment	O
or	O
alginate	O
only	O
was	O
observed	O
.	O

At	O
12	O
weeks	O
post	O
-	O
transplantation	O
,	O
the	O
defects	O
showed	O
very	O
poor	O
cartilage	O
repair	O
(	O
Additional	O
file	O
1	O
),	O
whose	O
surface	O
was	O
concave	O
,	O
irregular	O
or	O
sometimes	O
empty	O
in	O
the	O
middle	O
and	O
few	O
regenerated	O
tissues	O
could	O
be	O
seen	O
at	O
peripheral	O
regions	O
,	O
meaning	O
that	O
this	O
size	O
of	O
articular	O
cartilage	O
defect	O
in	O
a	O
rat	B-OG
joint	O
is	O
a	O
critical	O
-	O
size	O
defect	O
that	O
cannot	O
heal	O
by	O
itself	O
.	O

Therefore	O
,	O
a	O
defect	O
only	O
without	O
BMSC	O
transplantation	O
(	O
no	O
treatment	O
or	O
alginate	O
only	O
)	O
was	O
not	O
included	O
in	O
the	O
present	O
study	O
.	O

Gross	O
and	O
histological	O
evaluations	O

Rats	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
with	O
an	O
intraperitoneal	O
injection	O
of	O
3	O
.	O
5	O
ml	O
/	O
kg	O
of	O
10	O
%	O
chloral	O
hydrate	O
.	O

The	O
entire	O
right	O
knee	O
was	O
dissected	O
,	O
and	O
a	O
distal	O
part	O
of	O
the	O
femur	O
was	O
then	O
extirpated	O
.	O

The	O
samples	O
from	O
each	O
group	O
were	O
examined	O
and	O
photographed	O
to	O
evaluate	O
the	O
degree	O
of	O
defect	O
repair	O
(	O
0	O
–	O
4	O
),	O
integration	O
to	O
border	O
zone	O
(	O
0	O
–	O
4	O
),	O
and	O
macroscopic	O
appearance	O
(	O
0	O
–	O
4	O
)	O
according	O
to	O
the	O
International	O
Cartilage	O
Repair	O
Society	O
(	O
ICRS	O
)	O
macroscopic	O
assessment	O
scale	O
for	O
cartilage	O
repair	O
[	O
27	O
].	O

After	O
gross	O
examination	O
,	O
samples	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
decalcified	O
in	O
20	O
%	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
(	O
pH	O
7	O
.	O
4	O
)	O
for	O
21	O
d	O
,	O
and	O
embedded	O
in	O
paraffin	O
.	O

Serial	O
5	O
-	O
mm	O
thick	O
sections	O
were	O
cut	O
in	O
a	O
horizontal	O
plane	O
across	O
the	O
joint	O
.	O

Two	O
sections	O
within	O
every	O
consecutive	O
ten	O
sections	O
were	O
stained	O
with	O
Safranin	O
-	O
O	O
/	O
Fast	O
green	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
the	O
one	O
with	O
better	O
morphology	O
was	O
used	O
for	O
quantification	O
.	O

The	O
cartilage	O
repair	O
was	O
scored	O
by	O
two	O
blinded	O
authors	O
(	O
K	O
.	O
T	O
.	O
and	O
Y	O
.	O
D	O
.)	O
using	O
a	O
method	O
described	O
by	O
Wakitani	O
[	O
28	O
].	O

In	O
brief	O
,	O
each	O
section	O
was	O
assigned	O
a	O
score	O
,	O
which	O
was	O
the	O
sum	O
of	O
cell	O
morphology	O
(	O
0	O
–	O
4	O
),	O
matrix	O
-	O
staining	O
(	O
0	O
–	O
3	O
),	O
surface	O
regularity	O
(	O
0	O
–	O
3	O
),	O
thickness	O
of	O
cartilage	O
(	O
0	O
–	O
3	O
),	O
and	O
integration	O
of	O
donor	O
with	O
host	O
(	O
0	O
–	O
3	O
).	O

The	O
expression	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
in	O
the	O
regenerated	O
tissue	O
was	O
analyzed	O
by	O
immunohistological	O
staining	O
.	O

After	O
antigen	O
retrieval	O
by	O
boiling	O
the	O
samples	O
in	O
sodium	O
citrate	O
buffer	O
,	O
the	O
sections	O
were	O
blocked	O
in	O
serum	O
for	O
30	O
min	O
,	O
followed	O
by	O
incubation	O
with	O
the	O
primary	O
antibody	O
in	O
a	O
humidified	O
chamber	O
at	O
4	O
°	O
C	O
overnight	O
.	O

A	O
biotinylated	O
secondary	O
antibody	O
was	O
added	O
for	O
30	O
min	O
on	O
day	O
2	O
,	O
followed	O
by	O
an	O
avidin	B-GP
-	O
biotinylated	O
horseradish	B-OG
peroxidase	B-GP
complex	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
directions	O
.	O

Finally	O
,	O
the	O
peroxidase	B-GP
activity	O
was	O
revealed	O
by	O
immersion	O
in	O
DAB	O
substrate	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
rabbit	B-OG
anti	O
-	O
Sox9	B-GP
,	O
and	O
rabbit	B-OG
anti	O
-	O
Col2A1	B-GP
(	O
both	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
).	O

To	O
characterize	O
the	O
changes	O
in	O
immunostaining	O
,	O
the	O
mean	O
optical	O
densities	O
(	O
MODs	O
)	O
were	O
obtained	O
from	O
ten	O
areas	O
of	O
regenerated	O
tissue	O
from	O
five	O
separate	O
samples	O
.	O

Culture	O
of	O
BMSCs	O
and	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O

The	O
isolation	O
and	O
culture	O
of	O
rat	B-OG
BMSCs	O
from	O
the	O
tibias	O
and	O
femurs	O
of	O
4	O
-	O
week	O
-	O
old	O
Wistar	B-OG
rats	I-OG
were	O
performed	O
as	O
described	O
previously	O
[	O
17	O
].	O

Briefly	O
,	O
the	O
rats	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
after	O
anesthesia	O
(	O
intraperitoneal	O
injection	O
of	O
10	O
%	O
chloral	O
hydrate	O
)	O
and	O
sterilized	O
using	O
75	O
%	O
ethanol	O
for	O
10	O
min	O
before	O
surgery	O
.	O

After	O
dissecting	O
the	O
metaphyseal	O
ends	O
of	O
the	O
bones	O
under	O
sterile	O
conditions	O
,	O
the	O
bone	O
marrow	O
cells	O
were	O
flushed	O
out	O
using	O
Dulbecco	O
’	O
s	O
modified	O
Eagle	O
’	O
s	O
medium	O
(	O
DMEM	O
)/	O
F12	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Gibco	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
),	O
50	O
mg	O
/	O
ml	O
of	O
L	O
-	O
ascorbic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
1	O
%	O
glutamine	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
100	O
mg	O
/	O
ml	O
of	O
streptomycin	O
and	O
penicillin	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
and	O
centrifuged	O
at	O
1000	O
rpm	O
for	O
5	O
min	O
.	O

The	O
cells	O
were	O
resuspended	O
and	O
expanded	O
in	O
T	O
-	O
25	O
flasks	O
(	O
Cyagen	O
Biosciences	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
with	O
DMEM	O
/	O
F12	O
medium	O
and	O
incubated	O
at	O
37	O
°	O
C	O
under	O
conditions	O
of	O
5	O
%	O
CO2	O
.	O

The	O
medium	O
was	O
changed	O
every	O
3	O
days	O
.	O

Upon	O
reaching	O
70	O
%–	O
80	O
%	O
confluence	O
,	O
adherent	O
cells	O
were	O
trypsinized	O
,	O
harvested	O
,	O
and	O
expanded	O
.	O

Cells	O
that	O
had	O
undergone	O
three	O
passages	O
were	O
used	O
in	O
subsequent	O
experiments	O
.	O

Chondrogenic	O
differentiation	O
of	O
BMSCs	O
was	O
performed	O
following	O
the	O
method	O
described	O
in	O
our	O
previous	O
work	O
[	O
17	O
].	O

Monolayer	O
culture	O
cells	O
in	O
T	O
-	O
25	O
flasks	O
were	O
trypsinized	O
,	O
washed	O
,	O
and	O
centrifuged	O
.	O

The	O
isolated	O
BMSCs	O
were	O
suspended	O
at	O
a	O
concentration	O
of	O
6	O
×	O
106	O
cells	O
/	O
ml	O
in	O
a	O
1	O
.	O
25	O
%	O
alginate	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
0	O
.	O
15	O
M	O
NaCl	O
,	O
and	O
then	O
the	O
cell	O
suspension	O
was	O
slowly	O
dropped	O
into	O
a	O
102	O
mM	O
CaCl2	O
solution	O
.	O

The	O
beads	O
were	O
cultured	O
in	O
six	O
-	O
well	O
plates	O
under	O
conditions	O
of	O
5	O
%	O
O2	O
with	O
DMEM	O
/	O
F12	O
medium	O
containing	O
1	O
%	O
insulin	B-GP
,	O
transferrin	B-GP
and	O
selenous	O
(	O
ITS	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
100	O
nM	O
dexamethasone	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
10	O
ng	O
/	O
ml	O
transforming	B-GP
growth	I-GP
factor	I-GP
-	I-GP
β1	I-GP
(	O
TGF	B-GP
-	I-GP
β1	I-GP
)	O
(	O
PeproTech	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
).	O

During	O
the	O
period	O
of	O
chondrogenic	O
differentiation	O
,	O
the	O
culture	O
medium	O
with	O
or	O
without	O
nicotine	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100μM	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
BMSCs	O
treated	O
with	O
nicotine	O
for	O
24	O
h	O
were	O
used	O
in	O
the	O
experiments	O
for	O
molecular	O
mechanism	O
detection	O
.	O

RNA	O
interference	O

siRNAs	O
for	O
NFATc2	B-GP
(	O
L	O
-	O
011778	O
)	O
were	O
purchased	O
from	O
Gene	O
Pharma	O
(	O
Shanghai	O
Gene	O
Pharma	O
Co	O
.).	O

The	O
scramble	O
-	O
sense	O
siRNA	O
targeted	O
the	O
sequence	O
5	O
’-	O
GGAAGCUACAGUGGAUAAATT	O
-	O
3	O
′,	O
and	O
the	O
scramble	O
antisense	O
siRNA	O
targeted	O
the	O
sequence	O
5	O
’-	O
UUUAUCCACUGUAGCUUCCTT	O
-	O
3	O
′.	O

In	O
brief	O
,	O
passage	O
3	O
BMSCs	O
were	O
plated	O
to	O
obtain	O
70	O
–	O
80	O
%	O
confluence	O
in	O
six	O
-	O
well	O
plates	O
and	O
transfected	O
with	O
si	O
-	O
NFATc2	B-GP
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
),	O
negative	O
control	O
siRNA	O
or	O
Lipofectamine	O
2000	O
only	O
.	O

After	O
6	O
h	O
of	O
transfection	O
,	O
fresh	O
medium	O
was	O
exchanged	O
.	O

The	O
expression	O
of	O
NFATc2	B-GP
was	O
detected	O
using	O
RT	O
-	O
qPCR	O
and	O
Western	O
blotting	O
.	O

Calcium	O
imaging	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP

P3	O
BMSC	O
cultures	O
in	O
35	O
mm	O
glass	O
-	O
bottomed	O
plates	O
were	O
prepared	O
.	O

The	O
cells	O
were	O
washed	O
using	O
Hank	O
’	O
s	O
solution	O
three	O
times	O
and	O
incubated	O
in	O
dye	O
loading	O
solution	O
containing	O
1μM	O
Fluo	O
-	O
3	O
AM	O
(	O
DoJinDo	O
,	O
Shanghai	O
,	O
China	O
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
and	O
then	O
at	O
room	O
temperature	O
for	O
an	O
additional	O
30	O
min	O
.	O

Before	O
nicotine	O
stimulation	O
,	O
PBS	O
buffer	O
was	O
used	O
to	O
wash	O
the	O
cells	O
three	O
times	O
.	O

The	O
fluorescence	O
was	O
measured	O
after	O
the	O
addition	O
of	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100	O
μM	O
nicotine	O
.	O

Measurements	O
were	O
performed	O
in	O
a	O
laser	O
scanning	O
confocal	O
microscope	O
(	O
Carl	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
)	O
by	O
collecting	O
data	O
points	O
every	O
5	O
s	O
over	O
20	O
min	O
using	O
LCS	O
Lite	O
confocal	O
software	O
.	O

The	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
was	O
measured	O
using	O
a	O
calcineurin	B-GP
assay	O
kit	O
(	O
A068	O
,	O
Nanjing	O
Jiancheng	O
Bioengineering	O
Institute	O
,	O
Nanjing	O
,	O
China	O
).	O

In	O
short	O
,	O
the	O
protein	O
of	O
BMSCs	O
was	O
extracted	O
and	O
quantified	O
,	O
the	O
enzymatic	O
reaction	O
was	O
initiated	O
using	O
calmodulin	B-GP
and	O
p	O
-	O
nitrophenyl	O
phosphate	O
(	O
PNPP	O
)	O
as	O
a	O
substrate	O
,	O
and	O
then	O
the	O
inorganic	O
phosphorus	O
content	O
was	O
measured	O
.	O

The	O
enzyme	O
activity	O
unit	O
of	O
calcineurin	B-GP
was	O
defined	O
as	O
the	O
amount	O
of	O
1	O
M	O
inorganic	O
phosphorus	O
produced	O
by	O
decomposing	O
1	O
mg	O
calcineurin	B-GP
from	O
the	O
substrate	O
PNPP	O
per	O
hour	O
,	O
and	O
the	O
results	O
were	O
expressed	O
as	O
U	O
/	O
mg	O
protein	O
.	O

Reverse	O
transcription	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O

Total	O
RNA	O
from	O
regenerated	O
tissues	O
and	O
BMSCs	O
was	O
extracted	O
using	O
the	O
Trizol	O
(	O
Invitrogen	O
)	O
reagent	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

The	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
a	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
kit	O
.	O

The	O
cDNA	O
was	O
amplified	O
using	O
a	O
one	O
-	O
step	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
reaction	O
.	O

The	O
PCR	O
products	O
of	O
all	O
of	O
the	O
subtypes	O
of	O
nAChR	B-GP
were	O
separated	O
by	O
electrophoresis	O
on	O
2	O
%	O
agarose	O
gels	O
.	O

The	O
relative	O
mRNA	O
expression	O
levels	O
of	O
the	O
Sox9	B-GP
and	O
Col2A1	B-GP
were	O
normalized	O
to	O
the	O
level	O
of	O
glyceraldehyde	B-GP
3	I-GP
-	I-GP
phosphate	I-GP
dehydrogenase	I-GP
(	O
GAPDH	B-GP
).	O

The	O
rat	B-OG
primer	O
sequences	O
and	O
annealing	O
temperatures	O
used	O
are	O
shown	O
in	O
Table	O
1	O
.	O
Table	O
1Primer	O
used	O
for	O
qPCRGeneForward	O
PrimerReverse	O
PrimerAnnealGAPDHGCAAGTTCAACGGCACAGGCCAGTAGACTCCACGACA60	B-GP
°	O
CCol2A1GAGTGGAAGAGCGGAGACTACTGCTCCATGTTGCAGAAGACTTTCA60	O
°	O
CSox9CCAGCAAGAACAAGCCACACCTTGCCCAGAGTCTTGCTGA60	O
°	O
Cα3	B-GP
-	I-GP
nAChRGGTGGATGACAAGACCAAAGCAGGGCAGGTAGAAGACAAGCA60	I-GP
°	O
Cα4	B-GP
-	I-GP
nAChRCACGGTCTTCGTGCTCAATGTCCTTGGTTGCAGATGTCACTC62	I-GP
°	O
Cα5	B-GP
-	I-GP
nAChRGCTGCGCTGCTCTTGATGGTCGTATGTCCACGAGCCGAAT60	I-GP
°	O
Cα7	O
-	O
nAChRACAATACTTCGCCAGCACCAGGCATTTTGCCACCATCAGG60	O
°	O
Cβ2	B-GP
-	I-GP
nAChRGGAGTGGGAAGATTACCGCCTCAAGTCGTCGTGGTTCTCGTTGCG60	I-GP
°	O
Cβ4	B-GP
-	I-GP
nAChRGATTCTCCCAAGTCAGAACCTTTAAGCTGGAGATTTGATGTGGTTA60	I-GP
°	O
CAbbreviations	O
:	O
PCR	O
polymerase	O
chain	O
reaction	O
,	O
GAPDH	B-GP
glyceraldehyde	B-GP
phosphate	I-GP
dehydrogenase	I-GP
,	O
Col2A1	B-GP
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
gene	O
,	O
Sox9	B-GP
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
mobility	I-GP
group	I-GP
box9	I-GP
,	O
nAChR	B-GP
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP

Western	O
blotting	O

To	O
obtain	O
total	O
protein	O
,	O
the	O
cells	O
were	O
harvested	O
and	O
dissolved	O
in	O
RIPA	O
(	O
Beyotime	O
,	O
Nanjing	O
,	O
China	O
)	O
buffer	O
.	O

The	O
protein	O
concentrations	O
were	O
determined	O
by	O
a	O
BCA	O
protein	O
assay	O
kit	O
.	O

Equal	O
amounts	O
of	O
protein	O
lysates	O
(	O
40	O
mg	O
/	O
lane	O
)	O
were	O
loaded	O
and	O
resolved	O
on	O
10	O
%	O
sodium	O
-	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
then	O
were	O
transferred	O
onto	O
nitrocellulose	O
filters	O
and	O
probed	O
with	O
rabbit	B-OG
anti	O
-	O
Col2A1	B-GP
,	O
Sox9	B-GP
,	O
β	B-GP
-	I-GP
actin	I-GP
,	O
histone	B-GP
3	I-GP
,	O
NFATc2	B-GP
(	O
1	O
:	O
900	O
)	O
(	O
all	O
from	O
Santa	O
Cruz	O
Biotechnology	O
),	O
and	O
p	O
-	O
NFATc2	B-GP
(	O
1	O
:	O
500	O
)	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
antibodies	O
at	O
4	O
°	O
C	O
overnight	O
.	O

After	O
incubation	O
with	O
a	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
secondary	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
),	O
the	O
blots	O
were	O
developed	O
by	O
enhanced	O
chemiluminescence	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
and	O
were	O
visualized	O
by	O
exposure	O
to	O
a	O
Fusion	O
FX	O
system	O
(	O
VilberLourmat	O
,	O
Marne	O
-	O
la	O
-	O
Vallee	O
,	O
France	O
).	O

The	O
protein	O
amounts	O
in	O
electrophoresis	O
gels	O
were	O
analyzed	O
with	O
the	O
Quantity	O
One	O
4	O
.	O
6	O
analysis	O
software	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

All	O
solutions	O
in	O
this	O
procedure	O
contained	O
a	O
mixture	O
of	O
protease	B-GP
and	O
phosphatase	B-GP
inhibitors	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
were	O
performed	O
as	O
previously	O
described	O
[	O
29	O
].	O

In	O
brief	O
,	O
6	O
×	O
106	O
cells	O
were	O
fixed	O
with	O
1	O
%	O
formaldehyde	O
and	O
quenched	O
by	O
glycine	O
.	O

The	O
cells	O
were	O
washed	O
three	O
times	O
with	O
PBS	O
and	O
then	O
harvested	O
in	O
ChIP	O
lysis	O
buffer	O
(	O
50	O
mMTris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
0	O
,	O
1	O
%	O
SDS	O
and	O
5	O
mM	O
EDTA	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
).	O

DNA	O
was	O
sonicated	O
to	O
400	O
–	O
600	O
bp	O
before	O
extensive	O
centrifugation	O
.	O

Four	O
volumes	O
of	O
ChIP	O
dilution	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
2	O
mM	O
EDTA	O
and	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
)	O
were	O
added	O
to	O
the	O
supernatant	O
.	O

The	O
resulting	O
lysate	O
was	O
then	O
incubated	O
with	O
protein	B-GP
G	I-GP
beads	O
(	O
GE	O
Healthcare	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
and	O
H3K9	O
(	O
Abcam	O
),	O
H3K14	O
(	O
Abcam	O
)	O
antibodies	O
at	O
4	O
°	O
C	O
overnight	O
.	O

The	O
beads	O
were	O
washed	O
five	O
times	O
and	O
DNA	O
was	O
eluted	O
in	O
ChIP	O
elution	O
buffer	O
(	O
0	O
.	O
1	O
M	O
NaHCO3	O
,	O
1	O
%	O
SDS	O
and	O
30	O
μg	O
/	O
ml	O
proteinase	B-GP
K	I-GP
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
).	O

The	O
elution	O
was	O
incubated	O
at	O
65	O
°	O
C	O
overnight	O
and	O
DNA	O
was	O
extracted	O
with	O
a	O
DNA	O
purification	O
kit	O
(	O
Tiangen	O
Biotech	O
,	O
Beijing	O
,	O
China	O
).	O

The	O
purified	O
DNA	O
was	O
assayed	O
by	O
quantitative	O
PCR	O
assays	O
were	O
repeated	O
at	O
least	O
three	O
times	O
.	O

Data	O
were	O
expressed	O
as	O
a	O
percentage	O
of	O
input	O
DNA	O
.	O

The	O
primer	O
information	O
is	O
in	O
Table	O
2	O
.	O
Table	O
2Primer	O
used	O
for	O
ChIPTranscriptSense	O
primerAntisense	O
primerProductAnneaSox9	O
(	O
327	O
~	O
429	O
)	O
GCTCGGAACTGTCTGGAAACGAAACCAGGGCTACTTGCAC103	O
bp60	O
°	O
CCol2A1	O
(	O
413	O
~	O
546	O
)	O
GCACCTAGGCGATCTGGTTAGAGCTGCTGGCTGACTCTTT134	O
bp60	O
°	O
CAbbreviations	O
:	O
ChiP	O
chromatin	O
immunoprecipitation	O
,	O
Col2A1	B-GP
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
gene	O
,	O
Sox9	B-GP
SRY	O
-	O
type	O
high	O
mobility	O
group	O
box	O
9	O

Immunoprecipitation	O

Immunoprecipitation	O
was	O
performed	O
following	O
the	O
method	O
described	O
in	O
a	O
previous	O
study	O
[	O
30	O
].	O

Cell	O
lysates	O
from	O
BMSCs	O
were	O
prepared	O
in	O
NP40	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
4	O
,	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
5	O
%	O
NP40	O
,	O
all	O
from	O
Sigma	O
)	O
or	O
high	O
-	O
salt	O
lysis	O
buffer	O
(	O
20	O
mM	O
HEPES	O
pH	O
7	O
.	O
4	O
,	O
10	O
%	O
glycerol	O
,	O
0	O
.	O
35	O
M	O
NaCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
mM	O
DTT	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
)	O
with	O
proteinase	B-GP
inhibitors	O
.	O

The	O
supernatant	O
was	O
then	O
incubated	O
with	O
protein	B-GP
G	I-GP
beads	O
(	O
GE	O
Healthcare	O
)	O
and	O
the	O
NFATc2	B-GP
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
°	O
C	O
for	O
4	O
h	O
.	O

Beads	O
conjugated	O
with	O
the	O
lysates	O
and	O
antibodies	O
were	O
collected	O
by	O
centrifugation	O
and	O
washed	O
three	O
times	O
with	O
lysis	O
buffer	O
.	O

The	O
final	O
amount	O
of	O
wash	O
buffer	O
was	O
aspirated	O
and	O
SDS	O
loading	O
buffer	O
was	O
added	O
to	O
the	O
beads	O
.	O

The	O
prepared	O
proteins	O
were	O
resolved	O
using	O
10	O
%	O
SDS	O
-	O
PAGE	O
and	O
then	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

Finally	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
antibodies	O
against	O
HDAC1	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
12	O
h	O
.	O

Chemiluminescence	O
was	O
detected	O
using	O
the	O
abovementioned	O
ECL	O
system	O
.	O

Statistical	O
analysis	O

SPSS	O
17	O
(	O
SPSS	O
Science	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
was	O
used	O
for	O
data	O
analysis	O
.	O

Quantitative	O
data	O
were	O
expressed	O
as	O
the	O
means	O
±	O
SEM	O
.	O

Data	O
of	O
two	O
groups	O
were	O
evaluated	O
with	O
independent	O
sample	O
Student	O
’	O
s	O
t	O
tests	O
,	O
and	O
the	O
comparisons	O
among	O
more	O
than	O
two	O
groups	O
were	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
Dunnett	O
’	O
s	O
post	O
hoc	O
Student	O
’	O
s	O
t	O
tests	O
.	O

The	O
macroscopic	O
and	O
histological	O
score	O
was	O
evaluated	O
using	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O

Nicotine	O
had	O
an	O
adverse	O
effect	O
on	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defect	O

To	O
evaluate	O
the	O
impact	O
of	O
nicotine	O
on	O
cartilage	O
defect	O
repair	O
,	O
we	O
used	O
a	O
femoral	O
trochlear	O
cartilage	O
defect	O
rat	B-OG
model	O
,	O
which	O
was	O
repaired	O
by	O
BMSC	O
transplantation	O
.	O

Nicotine	O
was	O
injected	O
at	O
1	O
.	O
0	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
).	O

The	O
effect	O
of	O
nicotine	O
on	O
cartilage	O
repair	O
was	O
analyzed	O
.	O

At	O
12	O
weeks	O
post	O
-	O
transplantation	O
,	O
no	O
abnormal	O
findings	O
suggested	O
rejection	O
or	O
infection	B-DS
,	O
such	O
as	O
severe	O
inflammation	O
or	O
extensive	O
fibrosis	O
,	O
and	O
no	O
synovial	O
edema	O
was	O
observed	O
in	O
either	O
group	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
defects	O
were	O
covered	O
with	O
smooth	O
regenerated	O
tissues	O
with	O
surrounding	O
cartilage	O
,	O
and	O
the	O
tissues	O
were	O
well	O
integrated	O
with	O
the	O
surrounding	O
cartilage	O
although	O
there	O
remained	O
part	O
of	O
a	O
depressed	O
tissue	O
with	O
a	O
demarcating	O
border	O
<	O
1	O
mm	O
(	O
Fig	O
.	O
1a	O
).	O

Safranin	O
O	O
staining	O
showed	O
that	O
the	O
cartilage	O
defect	O
was	O
filled	O
to	O
the	O
full	O
depth	O
and	O
smooth	O
regenerated	O
tissues	O
with	O
good	O
column	O
alignment	O
,	O
which	O
were	O
well	O
integrated	O
with	O
both	O
edges	O
of	O
normal	O
cartilage	O
,	O
and	O
the	O
graft	O
had	O
a	O
normal	O
matrix	O
-	O
staining	O
compared	O
with	O
adjacent	O
cartilage	O
.	O

The	O
cell	O
morphology	O
was	O
similar	O
to	O
the	O
native	O
cartilage	O
,	O
which	O
was	O
round	O
or	O
ovoid	O
shaped	O
in	O
neat	O
rows	O
and	O
obvious	O
lacuna	O
(	O
Fig	O
.	O
1d	O
).	O

In	O
the	O
experimental	O
group	O
,	O
part	O
of	O
the	O
regenerated	O
tissues	O
had	O
a	O
fibrillated	O
surface	O
,	O
most	O
parts	O
of	O
the	O
defects	O
were	O
filled	O
with	O
regenerated	O
tissues	O
level	O
with	O
the	O
surrounding	O
cartilage	O
,	O
little	O
was	O
clearly	O
distinguishable	O
from	O
the	O
normal	O
cartilage	O
,	O
and	O
part	O
of	O
the	O
graft	O
had	O
a	O
fibrillated	O
surface	O
(	O
Fig	O
.	O
1b	O
).	O

The	O
marked	O
reduced	O
safranin	O
-	O
O	O
staining	O
was	O
exhibited	O
in	O
regenerated	O
tissues	O
,	O
which	O
fully	O
covered	O
the	O
defect	O
.	O

The	O
cell	O
morphology	O
was	O
almost	O
the	O
same	O
as	O
fibrocartilage	O
,	O
which	O
showed	O
an	O
irregular	O
arrangement	O
and	O
no	O
lacuna	O
(	O
Fig	O
.	O
1e	O
).	O

The	O
macroscopic	O
scores	O
of	O
the	O
control	O
group	O
were	O
much	O
higher	O
than	O
those	O
of	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
1c	O
),	O
and	O
the	O
microscopic	O
scores	O
in	O
the	O
control	O
group	O
were	O
much	O
lower	O
than	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
1f	O
).	O

The	O
result	O
suggested	O
that	O
the	O
transplantation	O
of	O
BMSCs	O
with	O
alginate	O
could	O
effectively	O
repair	O
the	O
cartilage	O
defect	O
as	O
the	O
regenerated	O
tissue	O
was	O
almost	O
the	O
same	O
as	O
hyaline	O
cartilage	O
.	O

Nicotine	O
had	O
an	O
obvious	O
adverse	O
effect	O
on	O
cell	O
morphology	O
of	O
the	O
regenerated	O
tissue	O
and	O
synthesis	O
of	O
cartilage	O
matrix	O
.	O
Fig	O
.	O
1Effects	O
of	O
nicotine	O
on	O
the	O
repair	O
of	O
the	O
cartilage	O
defect	O
with	O
BMSCs	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
and	O
b	O
Macroscopic	O
observation	O
of	O
cartilage	O
repair	O
(×	O
100	O
).	O
c	O
Macroscopic	O
scores	O
of	O
cartilage	O
repair	O
.	O
d	O
and	O
e	O
Safranin	O
-	O
O	O
and	O
fast	O
green	O
staining	O
of	O
cartilage	O
repair	O
(×	O
100	O
).	O
f	O
Histological	O
scores	O
of	O
cartilage	O
repair	O
.	O

Data	O
represent	O
mean	O
±	O
SD	O
(	O
n	O
=	O
8	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O
Scale	O
bar	O
=	O
200	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

Nicotine	O
inhibited	O
cartilage	O
repair	O
by	O
suppressing	O
Sox9	B-GP
expression	O

To	O
explore	O
the	O
mechanism	O
of	O
nicotine	O
’	O
s	O
suppression	O
on	O
the	O
chondrogenic	O
cartilage	O
repair	O
of	O
the	O
cartilage	O
defect	O
,	O
we	O
measured	O
the	O
expression	O
of	O
matrix	O
and	O
Sox9	B-GP
in	O
the	O
regenerated	O
tissues	O
.	O

Immunohistochemical	O
staining	O
of	O
sections	O
with	O
Col2A1	B-GP
and	O
Sox9	B-GP
antibodies	O
showed	O
the	O
proteins	O
in	O
the	O
regenerated	O
tissue	O
stained	O
positive	O
.	O

The	O
staining	O
of	O
Col2A1	B-GP
was	O
stronger	O
in	O
the	O
control	O
group	O
than	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
2a	O
and	O
b	O
),	O
similar	O
to	O
Sox9	B-GP
(	O
Fig	O
.	O
2d	O
and	O
e	O
).	O

The	O
mean	O
optical	O
densities	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
were	O
reduced	O
in	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
2c	O
and	O
f	O
).	O

RNA	O
was	O
extracted	O
from	O
the	O
regenerated	O
tissues	O
of	O
both	O
groups	O
,	O
and	O
the	O
mRNA	O
expression	O
of	O
aggrecan	B-GP
,	O
Col2A1	B-GP
,	O
and	O
Sox9	B-GP
in	O
the	O
experimental	O
group	O
were	O
decreased	O
(	O
Fig	O
.	O
2g	O
),	O
which	O
was	O
consistent	O
with	O
protein	O
expression	O
by	O
immunostaining	O
.	O

These	O
findings	O
demonstrated	O
that	O
nicotine	O
inhibited	O
the	O
expression	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

As	O
Sox9	B-GP
is	O
the	O
upstream	O
cellular	O
signal	O
of	O
Col2A1	B-GP
,	O
we	O
concluded	O
that	O
nicotine	O
decreased	O
the	O
expression	O
of	O
Col2A1	B-GP
by	O
suppressing	O
Sox9	B-GP
and	O
then	O
negatively	O
influenced	O
the	O
cartilage	O
defect	O
repair	O
.	O
Fig	O
.	O
2Effects	O
of	O
nicotine	O
on	O
the	O
regenerated	O
tissue	O
of	O
cartilage	O
defect	O
with	O
BMSCs	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
and	O
b	O
Immunohistological	O
staining	O
of	O
Col2A1	B-GP
in	O
regenerated	O
tissue	O
(×	O
100	O
).	O
c	O
Quantification	O
of	O
the	O
MOD	O
of	O
Col2A1	B-GP
.	O
d	O
and	O
e	O
Immunohistological	O
staining	O
of	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
(×	O
100	O
).	O
f	O
Quantification	O
of	O
the	O
MOD	O
of	O
Sox9	B-GP
.	O
g	O
mRNA	O
expression	O
of	O
Col2A	B-GP
,	O
aggrecan	B-GP
and	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

Data	O
represent	O
mean	O
±	O
SD	O
(	O
n	O
=	O
8	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O
Scale	O
bar	O
=	O
200	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
,	O
MOD	O
mean	O
optical	O
density	O
,	O
Sox9	B-GP
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP

Nicotine	O
increased	O
the	O
intracellular	O
Ca2	O
+	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
through	O
α7	B-GP
-	I-GP
nAChR	I-GP

To	O
investigate	O
the	O
mechanism	O
of	O
nicotine	O
’	O
s	O
suppression	O
on	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
0	O
.	O
1	O
to	O
100μM	O
nicotine	O
treatment	O
was	O
used	O
in	O
BMSCs	O
.	O

The	O
intracellular	O
signals	O
were	O
tested	O
to	O
verify	O
whether	O
the	O
Ca2	O
+/	O
CaN	B-GP
/	O
NFAT	B-GP
pathway	O
mediated	O
the	O
inhibitory	O
effect	O
of	O
nicotine	O
.	O

We	O
performed	O
a	O
calcium	O
imaging	O
assay	O
for	O
P3	O
BMSCs	O
.	O

The	O
results	O
showed	O
that	O
the	O
fluorescence	O
intensity	O
of	O
BMSCs	O
increased	O
5	O
–	O
10	O
min	O
after	O
administering	O
nicotine	O
and	O
that	O
the	O
slope	O
of	O
the	O
fluorescence	O
intensity	O
curve	O
was	O
different	O
,	O
which	O
grew	O
gradually	O
with	O
increasing	O
nicotine	O
exposure	O
.	O

Nicotine	O
elicited	O
an	O
increase	O
of	O
intracellular	O
calcium	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
3a	O
).	O

The	O
onset	O
time	O
of	O
nicotine	O
in	O
our	O
research	O
was	O
5	O
–	O
10	O
min	O
due	O
to	O
the	O
process	O
of	O
nicotine	O
’	O
s	O
diffusion	O
into	O
BMSCs	O
.	O

Thus	O
,	O
we	O
measured	O
the	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
in	O
0	O
.	O
5	O
h	O
after	O
nicotine	O
stimulus	O
and	O
found	O
that	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
was	O
also	O
increased	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
3b	O
).	O
Fig	O
.	O
3Effects	O
of	O
nicotine	O
on	O
intracellular	O
Ca2	O
+	O
concentration	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
immediately	O
(	O
a	O
and	O
d	O
)	O
and	O
30	O
mins	O
(	O
b	O
)	O
after	O
nicotine	O
stimulus	O
of	O
in	O
-	O
vitro	O
culture	O
.	O
a	O
Change	O
of	O
fluorescence	O
intensity	O
of	O
Ca2	O
+	O
after	O
the	O
stimulus	O
of	O
nicotine	O
at	O
different	O
concentrations	O
.	O
b	O
Change	O
of	O
fluorescence	O
intensity	O
of	O
calcineurin	B-GP
phosphatase	B-GP
activity	O
of	O
CaN	B-GP
calcineurin	B-GP
after	O
the	O
stimulus	O
of	O
nicotine	O
at	O
different	O
concentrations	O
.	O
c	O
Expression	O
of	O
the	O
subtypes	O
of	O
nAChR	B-GP
in	O
BMSCs	O
.	O
d	O
Effects	O
of	O
MLA	O
on	O
nicotine	O
’	O
s	O
augmentation	O
of	O
intracellular	O
Ca2	O
+	O
concentration	O
in	O
BMSCs	O
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
Scale	O
bar	O
=	O
100	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
CaN	B-GP
calcineurin	B-GP
,	O
MLA	O
methyllycaconitine	O
,	O
nAChR	B-GP
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP
,	O

Because	O
nAChR	B-GP
in	O
MSCs	O
has	O
a	O
large	O
Ca2	O
+	O
permeability	O
and	O
induces	O
elevated	O
intracellular	O
free	O
calcium	O
by	O
releasing	O
intracellular	O
calcium	O
stores	O
,	O
we	O
verified	O
whether	O
nicotine	O
exerted	O
its	O
effect	O
through	O
nAChR	B-GP
in	O
BMSCs	O
.	O

Total	O
RNA	O
and	O
proteins	O
were	O
extracted	O
from	O
BMSCs	O
,	O
and	O
an	O
examination	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
showed	O
that	O
α7	B-GP
-	I-GP
nAchR	I-GP
was	O
expressed	O
in	O
BMSCs	O
(	O
Fig	O
.	O
3c	O
).	O

We	O
found	O
that	O
10μM	O
methyllycaconitine	O
(	O
MLA	O
),	O
the	O
specific	O
antagonist	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
conversely	O
eliminated	O
the	O
nicotine	O
-	O
induced	O
calcium	O
influx	O
(	O
Fig	O
.	O
3d	O
),	O
implying	O
that	O
the	O
effect	O
of	O
nicotine	O
on	O
BMSCs	O
was	O
fulfilled	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O

Nicotine	O
suppressed	O
Sox9	B-GP
by	O
activating	O
the	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
pathway	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP

Nicotine	O
exposure	O
increased	O
the	O
concentration	O
of	O
Ca2	O
+	O
and	O
calcineurin	B-GP
phosphatase	B-GP
activity	O
increased	O
over	O
a	O
short	O
period	O
.	O

To	O
detect	O
the	O
molecular	O
mechanism	O
of	O
nicotine	O
’	O
s	O
negative	O
effect	O
,	O
BMSCs	O
were	O
treated	O
with	O
nicotine	O
at	O
different	O
times	O
to	O
detect	O
the	O
expression	O
change	O
of	O
Sox9	B-GP
.	O

The	O
results	O
showed	O
that	O
the	O
mRNA	O
expression	O
of	O
Sox9	B-GP
decreased	O
in	O
24	O
h	O
after	O
nicotine	O
exposure	O
(	O
Fig	O
.	O
4a	O
-	O
c	O
),	O
and	O
the	O
protein	O
expression	O
of	O
Sox9	B-GP
also	O
declined	O
(	O
Fig	O
.	O
4d	O
and	O
e	O
).	O

The	O
NFAT	B-GP
protein	O
has	O
calcineurin	B-GP
binding	O
sites	O
in	O
the	O
regulatory	O
domain	O
and	O
is	O
regulated	O
by	O
Ca2	B-GP
+	I-GP
and	I-GP
calmodulin	I-GP
-	I-GP
dependent	I-GP
serine	I-GP
phosphatase	I-GP
calcineurin	B-GP
[	O
22	O
];	O
therefore	O
,	O
we	O
extracted	O
the	O
total	O
protein	O
,	O
cytoplasmic	O
proteins	O
and	O
nucleoproteins	B-GP
and	O
found	O
that	O
although	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
expression	O
of	O
NFATc2	B-GP
of	O
whole	O
cells	O
(	O
Fig	O
.	O
4f	O
and	O
g	O
),	O
the	O
expression	O
of	O
nucleic	O
NFATc2	B-GP
protein	O
was	O
elevated	O
(	O
Fig	O
.	O
4h	O
and	O
i	O
)	O
and	O
the	O
cytoplasm	O
phosphorylated	O
NFATc2	B-GP
was	O
reduced	O
by	O
nicotine	O
(	O
Fig	O
.	O
4j	O
and	O
k	O
),	O
indicating	O
that	O
NFATc2	B-GP
was	O
rapidly	O
dephosphorylated	O
and	O
localized	O
to	O
the	O
nucleus	O
following	O
nicotine	O
treatment	O
and	O
that	O
the	O
dephosphorylated	O
NFATc2	B-GP
remains	O
in	O
the	O
nucleus	O
in	O
the	O
continued	O
presence	O
of	O
nicotine	O
.	O

To	O
further	O
verify	O
the	O
molecular	O
mechanism	O
of	O
nicotine	O
’	O
s	O
suppression	O
of	O
Sox9	B-GP
,	O
we	O
performed	O
RNAi	O
-	O
mediated	O
stable	O
knockdown	O
of	O
NFATc2	B-GP
expression	O
in	O
cultured	O
BMSCs	O
.	O
NFATc2	B-GP
expression	O
was	O
significantly	O
suppressed	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
(	O
Fig	O
.	O
4l	O
and	O
m	O
).	O

The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
Sox9	B-GP
had	O
no	O
change	O
when	O
10	O
μM	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
were	O
given	O
0	O
.	O
5	O
h	O
before	O
the	O
nicotine	O
exposure	O
(	O
Fig	O
.	O
4n	O
and	O
o	O
),	O
implying	O
that	O
interventions	O
aimed	O
at	O
α7	B-GP
-	I-GP
nAChR	I-GP
and	O
NFATc2	B-GP
could	O
reverse	O
nicotine	O
’	O
s	O
suppressive	O
effect	O
on	O
the	O
expression	O
of	O
Sox9	B-GP
.	O

Therefore	O
,	O
nicotine	O
suppressed	O
Sox9	B-GP
by	O
activating	O
the	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
pathway	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O
Fig	O
.	O
4Effects	O
of	O
nicotine	O
on	O
Sox9	B-GP
and	O
NFATc2	B-GP
expression	O
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	O
for	O
8	O
h	O
.	O
b	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	O
for	O
16	O
h	O
.	O
c	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	O
for	O
24	O
h	O
.	O
d	O
and	O
e	O
Protein	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	O
for	O
24	O
h	O
.	O
f	O
and	O
g	O
Expression	O
of	O
NFATc2	B-GP
in	O
nucleoproteins	B-GP
with	O
stimulus	O
of	O
nicotine	O
for	O
24	O
h	O
.	O
h	O
and	O
i	O
Expression	O
of	O
phosphorylated	O
NFATc2	B-GP
in	O
the	O
cytoplasm	O
with	O
stimulus	O
of	O
nicotine	O
for	O
24	O
h	O
.	O
j	O
and	O
k	O
Expression	O
of	O
NFATc2	B-GP
in	O
total	O
protein	O
with	O
stimulus	O
of	O
nicotine	O
for	O
24	O
h	O
.	O
l	O
and	O
m	O
Effect	O
of	O
Si	O
-	O
NFATc2	B-GP
in	O
BMSCs	O
.	O
n	O
and	O
o	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	O
’	O
s	O
suppression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
,	O
MLA	O
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP
,	O
Sox9	B-GP
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP

Nicotine	O
decreased	O
the	O
histone	B-GP
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
in	O
BMSCs	O

Nicotine	O
exposure	O
resulted	O
in	O
the	O
dephosphorylation	O
and	O
increased	O
the	O
nucleic	O
translocation	O
of	O
NFATc2	B-GP
,	O
and	O
then	O
NFATc2	B-GP
could	O
bind	O
to	O
a	O
site	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
target	O
gene	O
and	O
play	O
a	O
role	O
in	O
the	O
downregulation	O
of	O
gene	O
expression	O
[	O
23	O
].	O

Given	O
the	O
finding	O
that	O
nicotine	O
exposure	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
Sox9	B-GP
expression	O
,	O
our	O
investigation	O
further	O
focused	O
on	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
.	O

The	O
result	O
of	O
ChIP	O
analysis	O
indicated	O
that	O
the	O
binding	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
on	O
the	O
Sox9	B-GP
promoter	O
was	O
increased	O
(	O
Fig	O
.	O
5c	O
and	O
d	O
)	O
and	O
that	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
on	O
the	O
Sox9	B-GP
promoter	O
were	O
reduced	O
(	O
Fig	O
.	O
5a	O
and	O
b	O
)	O
while	O
a	O
decreased	O
binding	O
of	O
Sox9	B-GP
on	O
Col2A1	B-GP
was	O
also	O
observed	O
(	O
Fig	O
.	O
5e	O
).	O

The	O
above	O
changes	O
induced	O
by	O
nicotine	O
were	O
characterized	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
when	O
treatment	O
of	O
10	O
μM	O
MLA	O
or	O
si	O
-	O
NFATc2	B-GP
was	O
performed	O
before	O
nicotine	O
exposure	O
,	O
the	O
levels	O
of	O
H3K9ac	O
and	O
H3K14ac	O
were	O
rescued	O
to	O
the	O
level	O
of	O
untreated	O
control	O
(	O
Fig	O
.	O
5f	O
and	O
g	O
),	O
and	O
the	O
induced	O
binding	O
of	O
Sox9	B-GP
on	O
Col2A1	B-GP
was	O
also	O
reversed	O
(	O
Fig	O
.	O
5h	O
).	O

Therefore	O
,	O
nicotine	O
treatment	O
resulted	O
in	O
dephosphorylation	O
and	O
increased	O
nucleic	O
translocation	O
of	O
NFATc2	B-GP
.	O

Then	O
,	O
NFATc2	B-GP
and	O
HDAC1	B-GP
bound	O
on	O
the	O
Sox9	B-GP
promoter	O
reduced	O
the	O
levels	O
of	O
H3K9ac	O
and	O
H3K14ac	O
on	O
the	O
Sox9	B-GP
promoter	O
and	O
decreased	O
Sox9	B-GP
expression	O
.	O

Reduced	O
binding	O
of	O
Sox9	B-GP
with	O
Col2A1	B-GP
further	O
decreased	O
Col2A1	B-GP
expression	O
.	O
Fig	O
.	O
5Effects	O
of	O
nicotine	O
on	O
histone	B-GP
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
in	O
BMSCs	O
.	O

Assay	O
were	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
Change	O
of	O
H3K9	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
b	O
Change	O
of	O
H3K14	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
c	O
Change	O
of	O
NFATc2	B-GP
binding	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
d	O
Change	O
of	O
1	O
binding	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
e	O
Change	O
of	O
Sox9	B-GP
binding	O
on	O
the	O
enhancer	O
of	O
Col2A1	B-GP
.	O
f	O
Effects	O
of	O
methyllycaconitine	O
(	O
MLA	O
)	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	O
’	O
s	O
suppression	O
of	O
H3K9	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
g	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	O
’	O
s	O
suppression	O
of	O
H3K14	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
h	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	O
’	O
s	O
suppression	O
of	O
Sox9	B-GP
binding	O
on	O
the	O
enhancer	O
of	O
Col2A1	B-GP
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	B-GP
chain	I-GP
of	I-GP
type	I-GP
II	I-GP
collagen	I-GP
,	O
HDAC1	B-GP
histone	B-GP
deacetylase1	I-GP
,	O
MLA	O
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP
,	O
Sox9	B-GP
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP

Nicotine	O
increased	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP

HDACs	B-GP
participate	O
in	O
decreasing	O
the	O
histone	B-GP
acetylation	O
level	O
of	O
gene	O
promoters	O
.	O

The	O
transcriptional	O
activity	O
of	O
NFAT	B-GP
proteins	O
can	O
regulate	O
gene	O
expression	O
negatively	O
depending	O
on	O
which	O
binding	O
partners	O
are	O
involved	O
.	O

Nicotine	O
exposure	O
resulted	O
in	O
the	O
binding	O
of	O
NFATc2	B-GP
to	O
Sox9	B-GP
and	O
decreasing	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
in	O
the	O
Sox9	B-GP
promoter	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
nicotine	O
-	O
induced	O
decreased	O
level	O
of	O
H3K9ac	O
and	O
H3K14ac	O
in	O
the	O
Sox9	B-GP
promoter	O
,	O
we	O
used	O
immunoprecipitation	O
to	O
measure	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC	B-GP
.	O

The	O
result	O
showed	O
that	O
the	O
interaction	O
of	O
NFATc2	B-GP
with	O
HDAC1	B-GP
was	O
enhanced	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
after	O
nicotine	O
exposure	O
(	O
Fig	O
.	O
6a	O
),	O
and	O
no	O
significant	O
change	O
of	O
interaction	O
was	O
observed	O
when	O
Si	O
-	O
NFATc2	B-GP
and	O
MLA	O
were	O
used	O
before	O
nicotine	O
treatment	O
(	O
Fig	O
.	O
6b	O
).	O

These	O
results	O
implied	O
that	O
NFATc2	B-GP
could	O
bind	O
to	O
the	O
Sox9	B-GP
promoter	O
and	O
recruit	O
HDAC1	B-GP
,	O
which	O
also	O
binds	O
to	O
the	O
Sox9	B-GP
promoter	O
to	O
form	O
the	O
complex	O
,	O
and	O
the	O
latter	O
could	O
reduce	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
in	O
the	O
Sox9	B-GP
promoter	O
and	O
decrease	O
the	O
expression	O
of	O
Sox9	B-GP
.	O
Fig	O
.	O
6Effects	O
of	O
nicotine	O
on	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
Interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
under	O
stimulus	O
of	O
nicotine	O
with	O
different	O
concentrations	O
.	O
b	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
induced	O
by	O
nicotine	O
.	O

IgG	B-GP
is	O
a	O
negative	O
control	O
.	O

Input	O
is	O
a	O
positive	O
control	O
.	O

NFATc2	B-GP
is	O
the	O
precipitated	O
protein	O
.	O

HDAC1	B-GP
is	O
the	O
protein	O
of	O
interest	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
HDAC1	B-GP
histone	B-GP
deacetylase1	I-GP
,	O
MLA	O
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
first	O
verified	O
the	O
adverse	O
effect	O
of	O
nicotine	O
on	O
the	O
chondrogenic	O
repair	O
function	O
of	O
BMSCs	O
in	O
rat	B-OG
articular	O
cartilage	O
defects	O
and	O
proposed	O
that	O
Sox9	B-GP
plays	O
a	O
key	O
role	O
in	O
this	O
process	O
.	O

Based	O
on	O
our	O
previous	O
study	O
,	O
we	O
further	O
confirmed	O
nicotine	O
’	O
s	O
suppression	O
of	O
Col2A1	B-GP
expression	O
and	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
the	O
mechanism	O
of	O
which	O
may	O
involve	O
decreasing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
through	O
activation	O
of	O
Ca2	O
+/	O
CaN	B-GP
/	O
NFAT	B-GP
signaling	O
.	O

The	O
altered	O
gene	O
expression	O
and	O
promoter	O
acetylation	O
patterns	O
could	O
be	O
blocked	O
by	O
antagonism	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
indicating	O
that	O
the	O
direct	O
effect	O
of	O
nicotine	O
is	O
mediated	O
by	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O

Therefore	O
,	O
nicotine	O
could	O
interfere	O
with	O
cartilage	O
repair	O
through	O
suppressing	O
Sox9	B-GP
expression	O
in	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

Nicotine	O
is	O
a	O
high	O
-	O
risk	O
factor	O
for	O
many	O
diseases	O
and	O
has	O
negative	O
effects	O
on	O
soft	O
and	O
bony	O
tissue	O
healing	O
[	O
11	O
,	O
12	O
],	O
which	O
can	O
also	O
influence	O
the	O
repair	O
of	O
cartilage	O
defects	O
and	O
suppress	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
[	O
13	O
,	O
17	O
].	O

However	O
,	O
the	O
mechanism	O
of	O
nicotine	O
’	O
s	O
adverse	O
effect	O
is	O
still	O
unclear	O
.	O

Previous	O
researches	O
had	O
clarified	O
the	O
chondrogenic	O
potential	O
of	O
MSCs	O
involved	O
in	O
cartilage	O
regeneration	O
[	O
28	O
,	O
31	O
].	O

Similarly	O
,	O
the	O
regenerated	O
tissue	O
in	O
our	O
study	O
could	O
have	O
been	O
differentiated	O
from	O
BMSCs	O
.	O

In	O
addition	O
to	O
their	O
differentiation	O
potential	O
,	O
the	O
paracrine	O
action	O
of	O
MSCs	O
was	O
also	O
believed	O
to	O
contribute	O
to	O
their	O
therapeutic	O
effects	O
[	O
32	O
,	O
33	O
],	O
unknown	O
factors	O
secreted	O
from	O
BMSCs	O
may	O
stimulate	O
chondrogenic	O
differentiation	O
in	O
the	O
repair	O
process	O
.	O

Thus	O
,	O
we	O
believed	O
the	O
mechanism	O
of	O
cartilage	O
repair	O
in	O
defect	O
was	O
associated	O
with	O
chondrogenic	O
differentiation	O
and	O
the	O
secretive	O
action	O
of	O
BMSCs	O
.	O
Sox9	B-GP
is	O
a	O
key	O
transcriptional	O
factor	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
chondrocyte	O
differentiation	O
and	O
cartilage	O
formation	O
[	O
18	O
].	O

In	O
the	O
initial	O
stage	O
of	O
chondrogenesis	O
,	O
mesenchymal	O
stem	O
cells	O
condense	O
and	O
then	O
differentiate	O
into	O
chondrocytes	O
.	O
Sox9	B-GP
can	O
bind	O
to	O
essential	O
sequences	O
in	O
the	O
Col2A1	B-GP
gene	O
at	O
chondrocyte	O
-	O
specific	O
enhancers	O
and	O
activate	O
its	O
expression	O
,	O
and	O
Sox9	B-GP
has	O
been	O
identified	O
as	O
a	O
regulator	O
of	O
the	O
chondrocyte	O
lineage	O
[	O
34	O
].	O

Research	O
had	O
shown	O
that	O
the	O
inactivation	O
of	O
Sox9	B-GP
in	O
limb	O
buds	O
before	O
mesenchymal	O
condensation	O
resulted	O
in	O
a	O
complete	O
absence	O
of	O
cartilage	O
.	O

A	O
delayed	O
development	O
of	O
cartilage	O
can	O
also	O
be	O
induced	O
when	O
the	O
Sox9	B-GP
gene	O
is	O
inactivated	O
after	O
chondrogenic	O
mesenchymal	O
condensation	O
[	O
35	O
].	O

Thus	O
,	O
Sox9	B-GP
is	O
essential	O
in	O
the	O
condensed	O
stage	O
of	O
MSCs	O
and	O
subsequent	O
differentiation	O
in	O
the	O
process	O
of	O
cartilage	O
formation	O
[	O
15	O
].	O

In	O
addition	O
,	O
Sox9	B-GP
also	O
plays	O
an	O
essential	O
role	O
in	O
the	O
physiological	O
control	O
of	O
cartilaginous	O
tissues	O
[	O
36	O
].	O

BMSCs	O
with	O
Sox9	B-GP
gene	O
transfer	O
by	O
adenovirus	B-OG
could	O
promote	O
cartilage	O
defect	O
repair	O
[	O
37	O
].	O

Therefore	O
,	O
Sox9	B-GP
also	O
play	O
an	O
important	O
role	O
in	O
cartilage	O
repair	O
using	O
BMSCs	O
.	O

Our	O
results	O
found	O
that	O
nicotine	O
reduced	O
Sox9	B-GP
expression	O
in	O
the	O
regenerated	O
tissue	O
in	O
the	O
cartilage	O
defect	O
area	O
,	O
which	O
demonstrated	O
that	O
nicotine	O
has	O
an	O
adverse	O
effect	O
on	O
cartilage	O
repair	O
through	O
the	O
suppression	O
of	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

Histone	B-GP
acetyltransferases	I-GP
(	O
HATs	B-GP
)	O
and	O
HDACs	B-GP
are	O
two	O
classes	O
of	O
histone	B-GP
acetylation	O
enzymes	O
,	O
which	O
determine	O
the	O
acetylation	O
status	O
of	O
histones	B-GP
of	O
genes	O
.	O

The	O
activated	O
balance	O
of	O
HATs	B-GP
and	O
HDACs	B-GP
affects	O
the	O
regulation	O
of	O
gene	O
expression	O
[	O
38	O
].	O

The	O
reduction	O
of	O
acetylation	O
in	O
the	O
transcriptional	O
regulatory	O
regions	O
often	O
leads	O
to	O
the	O
inhibition	O
of	O
gene	O
expression	O
[	O
39	O
].	O

The	O
Sox9	B-GP
-	O
based	O
transcriptional	O
complex	O
,	O
including	O
CBP	B-GP
/	O
p300	B-GP
,	O
which	O
has	O
an	O
intrinsic	O
HATs	B-GP
activity	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	O
of	O
chondrogenic	O
differentiation	O
of	O
MSCs	O
[	O
19	O
].	O

Thus	O
,	O
the	O
expression	O
of	O
Sox9	B-GP
itself	O
is	O
mainly	O
regulated	O
by	O
histone	B-GP
acetylation	O
[	O
20	O
].	O

Histone	B-GP
acetylation	O
is	O
concentrated	O
mainly	O
on	O
histone	B-GP
3	I-GP
and	O
histone	B-GP
4	I-GP
[	O
40	O
],	O
and	O
H3K9	O
and	O
H3K14	O
acetylation	O
often	O
co	O
-	O
occur	O
at	O
many	O
gene	O
regulatory	O
elements	O
and	O
adjust	O
the	O
gene	O
expression	O
in	O
stem	O
cells	O
[	O
41	O
].	O

Based	O
on	O
these	O
data	O
,	O
we	O
focused	O
on	O
nicotine	O
’	O
s	O
regulation	O
of	O
H3K9	O
and	O
H3K14	O
acetylation	O
of	O
Sox9	B-GP
during	O
the	O
process	O
of	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

We	O
observed	O
that	O
nicotine	O
could	O
reduce	O
the	O
expression	O
of	O
Sox9	B-GP
through	O
decreasing	O
H3K9	O
and	O
H3K14	O
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
and	O
finally	O
suppress	O
the	O
chondrogenic	O
differentiation	O
potential	O
of	O
BMSCs	O
.	O

Our	O
in	O
vitro	O
data	O
are	O
consistent	O
with	O
the	O
in	O
vivo	O
results	O
where	O
nicotine	O
directly	O
decreased	O
the	O
expression	O
of	O
Sox9	B-GP
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
by	O
suppressing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
during	O
the	O
process	O
of	O
BMSCs	O
chondrogenic	O
differentiation	O
.	O

NFAT	B-GP
is	O
a	O
family	O
of	O
transcription	B-GP
factors	I-GP
critical	O
in	O
regulating	O
early	O
gene	O
transcription	O
in	O
response	O
to	O
T	B-GP
cell	I-GP
receptor	I-GP
-	O
mediated	O
signals	O
in	O
lymphocytes	O
[	O
42	O
].	O
NFATc2	B-GP
is	O
a	O
repressor	O
of	O
chondrogenesis	O
[	O
21	O
]	O
and	O
can	O
induce	O
gene	O
silencing	O
through	O
interaction	O
with	O
HDAC	B-GP
[	O
22	O
].	O

Our	O
study	O
demonstrated	O
that	O
NFATc2	B-GP
could	O
bind	O
with	O
Sox9	B-GP
and	O
recruit	O
HDAC1	B-GP
to	O
decrease	O
the	O
histone	B-GP
acetylation	O
of	O
theSox9	O
promoter	O
.	O

Calcineurin	B-GP
(	O
also	O
called	O
protein	B-GP
phosphatase	I-GP
2B	I-GP
),	O
the	O
only	O
serine	B-GP
/	I-GP
threonine	I-GP
protein	I-GP
phosphatase	I-GP
under	O
the	O
control	O
of	O
Ca2	O
+/	O
calmodulin	B-GP
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
coupling	O
of	O
Ca2	O
+	O
signals	O
to	O
cellular	O
responses	O
[	O
43	O
].	O

Ca2	O
+	O
is	O
the	O
upstream	O
signaling	O
molecule	O
of	O
calcineurin	B-GP
,	O
and	O
the	O
increased	O
Ca2	O
+	O
can	O
activate	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
.	O

The	O
complex	O
regulation	O
of	O
calcineurin	B-GP
can	O
dephosphorylate	O
phosphorylated	O
serine	O
/	O
threonine	O
proteins	O
and	O
initiate	O
multiple	O
pathways	O
.	O

NFATc2	B-GP
is	O
the	O
downstream	O
signal	O
of	O
calcineurin	B-GP
[	O
44	O
],	O
and	O
the	O
response	O
to	O
an	O
increase	O
of	O
intracellular	O
Ca2	O
+	O
is	O
dependent	O
upon	O
the	O
dephosphorylation	O
of	O
NFATc2	B-GP
by	O
calcineurin	B-GP
.	O

The	O
activated	O
calcineurin	B-GP
controls	O
the	O
translocation	O
of	O
NFAT	B-GP
proteins	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
regulates	O
the	O
expression	O
of	O
target	O
genes	O
[	O
23	O
].	O

Neuronal	O
nAchR	B-GP
is	O
usually	O
in	O
excitable	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
and	O
controls	O
the	O
influx	O
and	O
efflux	O
of	O
Na	O
+,	O
K	O
+,	O
and	O
Ca2	O
+	O
[	O
45	O
].	O

Recent	O
studies	O
found	O
that	O
nAchR	B-GP
was	O
also	O
in	O
non	O
-	O
excitable	O
cells	O
outside	O
the	O
nervous	O
system	O
[	O
24	O
,	O
46	O
],	O
providing	O
physiologic	O
functions	O
in	O
these	O
cells	O
[	O
47	O
],	O
in	O
which	O
Ca2	O
+	O
plays	O
an	O
important	O
role	O
in	O
a	O
signaling	O
cascade	O
activated	O
by	O
nAchR	B-GP
.	O

Stimulation	O
of	O
MSCs	O
with	O
nicotine	O
induced	O
increases	O
of	O
intracellular	O
Ca2	O
+	O
concentration	O
and	O
initiated	O
the	O
downstream	O
pathway	O
of	O
cascade	O
activation	O
while	O
MLA	O
,	O
which	O
is	O
the	O
specific	O
antagonist	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
could	O
inhibit	O
the	O
calcium	O
influx	O
[	O
48	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
α7	B-GP
-	I-GP
nAChR	I-GP
was	O
presented	O
in	O
BMSCs	O
and	O
a	O
nicotine	O
stimulus	O
could	O
increase	O
intracellular	O
Ca2	O
+	O
and	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
of	O
BMSCs	O
.	O

The	O
expression	O
of	O
dephosphorylated	O
NFATc2	B-GP
in	O
the	O
cytoplasm	O
decreased	O
and	O
NFATc2	B-GP
in	O
the	O
nucleus	O
increased	O
.	O

Therefore	O
,	O
nicotine	O
could	O
activate	O
Ca2	O
+/	O
Calcineurin	B-GP
/	O
NFAT	B-GP
signaling	O
in	O
BMSCs	O
throughα7	O
-	O
nAChR	B-GP
,	O
resulting	O
in	O
recruitment	O
of	O
HDAC1	B-GP
,	O
which	O
decreased	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
and	O
finally	O
inhibited	O
BMSC	O
chondrogenic	O
differentiation	O
.	O

The	O
dose	O
of	O
nicotine	O
exposure	O
in	O
our	O
study	O
is	O
2	O
mg	O
/	O
kg	O
/	O
d	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
animal	B-OG
studies	O
[	O
49	O
,	O
50	O
].	O

According	O
to	O
a	O
previous	O
investigation	O
,	O
an	O
average	O
tobacco	O
rod	O
contains	O
10	O
–	O
14	O
mg	O
of	O
nicotine	O
,	O
and	O
on	O
average	O
,	O
approximately	O
1	O
.	O
5	O
mg	O
of	O
nicotine	O
is	O
absorbed	O
systemically	O
during	O
smoking	O
[	O
51	O
].	O

Based	O
on	O
the	O
dose	O
–	O
conversion	O
correlation	O
between	O
humans	B-OG
and	O
rats	B-OG
(	O
human	B-OG
:	O
rats	B-OG
=	O
1	O
:	O
6	O
.	O
17	O
)	O
[	O
52	O
],	O
the	O
dose	O
of	O
nicotine	O
exposure	O
in	O
the	O
present	O
study	O
is	O
equivalent	O
to	O
the	O
nicotine	O
exposure	O
in	O
an	O
adult	O
weighing	O
approximately	O
70	O
kg	O
smoking	O
2	O
.	O
3	O
cigarettes	O
per	O
day	O
(	O
calculated	O
as	O
follows	O
:	O
2	O
mg	O
/	O
kg	O
/	O
d	O
÷	O
6	O
.	O
17	O
×	O
70	O
kg	O
÷	O
10	O
mg	O
/	O
cigarette	O
=	O
2	O
.	O
3	O
cigarettes	O
/	O
d	O
).	O

The	O
definition	O
of	O
nicotine	B-DS
dependence	I-DS
is	O
the	O
equivalent	O
of	O
more	O
than	O
ten	O
cigarettes	O
per	O
day	O
,	O
and	O
each	O
cigarette	O
contains	O
at	O
least	O
0	O
.	O
5	O
mg	O
nicotine	O
[	O
53	O
].	O

The	O
dose	O
of	O
nicotine	O
in	O
our	O
study	O
was	O
lower	O
than	O
the	O
actual	O
exposure	O
of	O
nicotine	B-DS
dependence	I-DS
in	O
daily	O
life	O
.	O

The	O
present	O
results	O
showed	O
the	O
obvious	O
impact	O
of	O
nicotine	O
on	O
cartilage	O
repair	O
.	O

Thus	O
nicotine	O
’	O
s	O
adverse	O
effect	O
with	O
nicotine	B-DS
dependence	I-DS
would	O
be	O
more	O
serious	O
.	O

The	O
concentration	O
of	O
nicotine	O
(	O
0	O
.	O
01	O
–	O
10	O
μM	O
)	O
used	O
in	O
our	O
chondrogenic	O
differentiation	O
model	O
is	O
consistent	O
with	O
those	O
often	O
used	O
in	O
pluripotent	O
stem	O
cell	O
studies	O
[	O
54	O
,	O
55	O
].	O

The	O
blood	O
concentrations	O
of	O
nicotine	O
during	O
daily	O
smoking	O
are	O
0	O
.	O
06	O
μM	O
to	O
0	O
.	O
23	O
μM	O
[	O
56	O
],	O
the	O
initial	O
concentration	O
of	O
nicotine	O
in	O
our	O
study	O
was	O
0	O
.	O
1	O
μM	O
,	O
which	O
was	O
within	O
the	O
range	O
of	O
a	O
daily	O
smoker	O
’	O
s	O
nicotinic	O
blood	O
concentration	O
and	O
could	O
suppress	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

Based	O
on	O
the	O
principle	O
of	O
toxicology	O
,	O
we	O
set	O
a	O
concentration	O
gradient	O
from	O
0	O
.	O
1	O
to	O
100	O
μM	O
.	O

The	O
result	O
showed	O
that	O
nicotinic	O
suppression	O
on	O
BMSC	O
chondrogenic	O
differentiation	O
has	O
concentration	O
-	O
dependent	O
characteristics	O
.	O

Although	O
the	O
largest	O
nicotine	O
exposure	O
used	O
in	O
the	O
present	O
study	O
was	O
100	O
μM	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
the	O
plasma	O
nicotine	O
level	O
of	O
nicotine	B-DS
dependence	I-DS
,	O
the	O
result	O
was	O
the	O
most	O
obvious	O
and	O
the	O
reversing	O
experiment	O
verified	O
the	O
key	O
point	O
of	O
the	O
molecular	O
mechanism	O
in	O
this	O
concentration	O
,	O
which	O
is	O
also	O
helpful	O
in	O
clarifying	O
the	O
molecular	O
mechanism	O
.	O

Conclusions	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
nicotine	O
at	O
a	O
dose	O
under	O
the	O
actual	O
exposure	O
of	O
nicotine	B-DS
dependence	I-DS
in	O
daily	O
life	O
had	O
an	O
adverse	O
effect	O
on	O
the	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defects	O
and	O
that	O
nicotine	O
suppressed	O
BMSC	O
chondrogenic	O
differentiation	O
via	O
the	O
activation	O
Ca2	O
+/	O
Calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
,	O
which	O
decreased	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
.	O

The	O
current	O
study	O
offers	O
insight	O
into	O
the	O
risk	O
assessment	O
of	O
cartilage	O
defect	O
repair	O
in	O
a	O
nicotine	O
exposure	O
population	O
,	O
advising	O
individuals	O
to	O
avoid	O
the	O
negative	O
impact	O
of	O
nicotine	O
on	O
BMSC	O
cartilage	O
repair	O
to	O
achieve	O
high	O
-	O
quality	O
repair	O
of	O
cartilage	O
tissue	O
.	O

Additional	O
file	O

Additional	O
file	O
1	O
:	O
Macroscopic	O
observation	O
of	O
cartilage	O
defect	O
with	O
no	O
treatment	O
and	O
alginate	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
Cartilage	O
defect	O
with	O
no	O
treatment	O
.	O
b	O
Cartilage	O
defect	O
with	O
alginate	O
only	O
.	O

(	O
DOCX	O
413	O
kb	O
)	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13287	O
-	O
018	O
-	O
0853	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

